Histone deacetylase inhibitors open new doors in cancer therapy.
about
Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathwayMacrocyclic histone deacetylase inhibitorsEvolution of the arginase fold and functional diversityNicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotauRon knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)Virtual screening and experimental validation of novel histone deacetylase inhibitorsA potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.Diversity-oriented synthesis: exploring the intersections between chemistry and biology.A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression.Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cellsThe effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?ER stress response plays an important role in aggregation of α-synucleinATM mediated phosphorylation of CHD4 contributes to genome maintenance.Positron emission tomography imaging of cancer biology: current status and future prospectsDesign of a novel nucleoside analog as potent inhibitor of the NAD dependent deacetylase, SIRT2Applications of molecular imaging.Epigenetic Contributions to the Relationship between Cancer and Dietary Intake of Nutrients, Bioactive Food Components, and Environmental Toxicants.Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agentsDietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?Recent advances in targeted therapy of human myelogenous leukaemia.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Dietary agents as histone deacetylase inhibitors.Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancerHodgkin's lymphoma: molecular targets and novel treatment strategies.Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist.Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.The Rubinstein-Taybi syndrome: modeling mental impairment in the mouse.In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitorsEBV reactivation as a target of luteolin to repress NPC tumorigenesis.Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells.Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoterA novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytesPET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.A role for cytoskeletal protein acetylation in modulating myometrial activity.Impact of Epigenetic Dietary Components on Cancer through Histone Modifications.Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.Autoacetylation regulates P/CAF nuclear localization.
P2860
Q21260429-BACB8272-E4FD-49C2-989E-334F33185FDDQ24629065-60393815-7926-4EC7-9D12-21261C5E7521Q24642568-E9ADC477-6574-4962-9B19-521F8829B276Q24651880-E4A4BB35-928E-4A9A-A97C-38BE4519F510Q28534954-A267F327-EDC6-4B4A-A099-4D3141C96C58Q28829470-694E16B3-133C-435C-8635-91A5AE192B08Q30578694-9D5AD139-C486-4E66-916F-F5E1F35C0199Q33231454-CE44DD00-7D7F-4340-AEB3-8A78B263120AQ33315739-A3B63015-9C6C-4F16-88CC-55E0FA3398EFQ34271529-BB814D62-05EA-4EDC-AAA9-29B47BC38F46Q34360342-881D9A48-1BDA-44F3-A2C5-B2F369751F9BQ34468291-0252E1B6-C783-4E9E-AAFC-36FD760179A3Q34557700-8A9E3DC0-41AA-4009-A380-8318AC60BE81Q34697688-4CDE0EC1-A523-499F-83AD-42275627132DQ34729139-09022693-834B-4296-9EC4-08C26277C1E8Q35082412-E9CF8E0A-65AA-4E2F-80E0-83F57F5B0DB9Q35697918-6BD5D7C0-7C46-4E47-B976-8FF2752FFEA0Q35733719-99DA6395-0284-4189-A4F0-3B9AA1A25A75Q36305199-D6965C24-D54E-4FBE-A532-1B0FE3470184Q36318531-131898AC-4ECC-4A60-A5A3-6B743EE7AF10Q36429727-4D167E1C-1DAC-42E0-BA32-C5493071269FQ36465484-951D57B0-01C9-4D78-B26D-BD5931842D60Q36537920-77C4CFDB-0A21-4BB2-901C-36BA4B054C6FQ36572545-301F355A-D934-4F07-ACD8-2314A1E87D2EQ36718441-2C2EA6AC-2B3E-4F1A-9F2B-AD2F0B4D16F6Q36763539-54F6FFA5-C823-410E-9AE9-543511EAFC4FQ36837326-B7ADAC5B-BE77-4798-9203-A9E4AA426794Q36931722-0CA83578-63D2-4EE3-B418-6C00F2B8687CQ37011621-860AD655-D2F5-4487-A4AB-602DFF8946EFQ37109915-DA5AFEAD-BD07-4AB9-A02D-7CB342EE1303Q37240767-1FF33D70-5305-4753-8F5B-5C65FB8F6821Q37281699-D175B7DD-FE81-44CF-9F2F-3BE0D3BC003AQ37294632-C767A8CF-396C-4FCC-9BD9-9260B13DC0BFQ37355387-79DEF37A-4E71-44D7-A699-3E6FA4D7D2C6Q37374442-1D2DEE36-ADE8-4AE9-9521-450610AEB7D0Q37993058-81D4FE36-3109-44F4-8693-3E3B8BD271B1Q38428453-C8528D11-E69E-49CF-B374-68C72BA664BBQ39430288-83F25764-BECF-4712-A733-F269341021DBQ40182128-F1692FB8-1207-4830-BC70-0FA310A67DDBQ42806222-B9A05E53-5057-43CA-85D5-951F399B59C1
P2860
Histone deacetylase inhibitors open new doors in cancer therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Histone deacetylase inhibitors open new doors in cancer therapy.
@ast
Histone deacetylase inhibitors open new doors in cancer therapy.
@en
type
label
Histone deacetylase inhibitors open new doors in cancer therapy.
@ast
Histone deacetylase inhibitors open new doors in cancer therapy.
@en
prefLabel
Histone deacetylase inhibitors open new doors in cancer therapy.
@ast
Histone deacetylase inhibitors open new doors in cancer therapy.
@en
P1476
Histone deacetylase inhibitors open new doors in cancer therapy.
@en
P2093
Fiona McLaughlin
Nicholas B La Thangue
P304
P356
10.1016/J.BCP.2004.05.034
P407
P577
2004-09-01T00:00:00Z